Expert perspectives on GLP-1 obesity treatment, incretin therapies, personalized obesity management, earlier intervention, access barriers, AI-enabled care and the future of obesity management.
The obesity treatment landscape is undergoing one of the most significant transformations in modern metabolic medicine. While GLP-1 obesity treatment has changed expectations around pharmacological weight management, the conversation is now moving beyond a single measure of success: how much weight a patient loses.
This survey of 25 U.S. Key Opinion Leaders highlights continued demand for therapeutic innovation, earlier intervention, improved treatment access, personalized obesity management, and greater integration of digital health and artificial intelligence.
As new incretin therapies, oral medicines, combination approaches, and emerging multimodal treatments enter the market, the future of obesity management is likely to be defined by much more than weight reduction alone.
Rated the need for continued innovation in obesity management as high or very high.
Considered current treatment options partially adequate, indicating that additional innovation is needed.
Considered earlier identification and treatment extremely or very important.
Considered digital health and AI likely or very likely to become part of obesity management.
The emerging model connects higher-efficacy therapies with oral options, personalized cardiometabolic assessment, earlier intervention, digital support, AI and sustainable patient access.
Expand efficacy and improve clinically meaningful outcomes in chronic weight management.
Increase convenience and flexibility through expanded oral treatment options.
Move beyond single-mechanism approaches toward combination and multi-agonist strategies.
Consider comorbidities, metabolic risk, body composition, treatment response and tolerability.
Support monitoring, adherence, treatment-response assessment and personalized engagement.
Translate scientific progress into affordable, sustainable and accessible real-world treatment.
Across the eight survey questions, the strongest signals point to continued unmet need, personalized care, earlier intervention, access challenges and confidence in digital health and AI-enabled obesity management.
Very High / High need for continued innovation in obesity management.
Rated earlier identification and treatment extremely or very important.
Optimistic / Very optimistic about the future of obesity management over the next decade.
Despite major progress in incretin-based medicines, KOL perspectives point to continued unmet needs around efficacy, tolerability, convenience, durability, treatment persistence, weight regain and broader cardiometabolic outcomes.
Even highly effective medicines can face challenges involving long-term adherence, tolerability, affordability, insurance coverage, continuity of care and weight regain following discontinuation.
The obesity treatment landscape is evolving toward higher-efficacy therapies, expanded oral options, greater convenience, more flexible treatment strategies and continued investment in chronic weight management.
Obesity is increasingly viewed as a heterogeneous chronic metabolic disease, with treatment decisions potentially considering cardiometabolic risk, comorbidities, body composition, treatment response and tolerability.
The emerging model is earlier identification → earlier treatment → complication prevention or modification → long-term disease management, supported by screening, referral and longitudinal monitoring.
Scientific innovation is accelerating, but the ability of patients to obtain and sustain treatment has not always kept pace, creating a disconnect between clinical potential and real-world care.
AI and digital health may support risk stratification, patient monitoring, adherence, lifestyle management, treatment-response assessment, weight-regain prediction, personalized engagement and clinical decision support.
The next phase of obesity care is expected to focus increasingly on durability, tolerability, convenience, lean-mass preservation, multimodal approaches and broader cardiometabolic outcomes.
When asked to identify the most important recent advancement, 76% of KOLs pointed to more effective incretin-based therapies and expansion into oral GLP-1 treatment.
The broader innovation pipeline is also moving toward combination approaches, multi-agonists and therapies designed to improve tolerability, durability and body-composition outcomes.
More effective incretin-based therapies and expanded oral treatment options were identified as the leading recent advancement.
Emerging approaches include amylin-based therapies, GLP-1/amylin combinations and broader multimodal treatment strategies.
Future innovation is expected to focus on long-term maintenance, tolerability and preserving lean mass alongside weight reduction.
Scientific progress is accelerating, but cost, insurance coverage and access restrictions can limit whether patients can obtain and sustain treatment.
Obesity requires longitudinal management, making digital health and AI relevant across the patient journey. 88% of surveyed KOLs considered these technologies likely or very likely to become part of obesity management.
Potential applications include risk stratification, patient monitoring, medication adherence support, lifestyle management, treatment-response assessment, weight-regain prediction, personalized engagement and clinical decision support.
The emerging model combines AI-powered insights, digital monitoring, clinician oversight and personalized patient engagement.
The survey points to a field moving from short-term weight reduction toward chronic disease management, personalized cardiometabolic care, earlier intervention, digital support and sustainable access.
Success is increasingly evaluated through durability, treatment persistence and long-term clinical outcomes rather than weight reduction alone.
The treatment landscape is expanding toward amylin-based therapies, GLP-1/amylin combinations, multi-agonists and other combination approaches.
Comorbidities, metabolic risk, body composition, treatment response and tolerability are becoming more relevant to treatment selection and adjustment.
KOLs emphasize more proactive care, including earlier screening, referral, integrated care and longitudinal monitoring.
The next phase combines therapeutic innovation with digital support, clinician oversight and sustainable patient access.
The future of obesity management is unlikely to be defined by one medicine or technology. Instead, it is moving toward an interconnected model of therapy, personalized cardiometabolic assessment, digital support and sustainable access.
The survey shows an obesity market where therapeutic innovation, personalization, earlier intervention, digital monitoring and access strategy are increasingly interconnected.
“The opportunity is no longer simply to develop a more effective obesity medicine. It is to build a connected care model.”
Future differentiation may increasingly depend on durability, tolerability, convenience, body-composition outcomes and broader cardiometabolic relevance.
As more therapies become available, treatment selection and adjustment may increasingly reflect comorbidities, metabolic risk, body composition, response and patient preferences.
The opportunity lies in clinically validated tools that improve monitoring, adherence, engagement and treatment-response assessment while augmenting clinician decision-making.
With 72% identifying cost, insurance restrictions and access limitations as the greatest barrier, sustainable access remains central to real-world impact.
These obesity KOL insights reveal a treatment landscape that is evolving rapidly but remains far from fully optimized.
GLP-1 obesity treatment and other incretin-based therapies have transformed expectations around pharmacological weight management. However, the findings from 25 U.S. KOLs demonstrate that continued innovation is still required to address treatment durability, personalization, access, tolerability and long-term outcomes.
The future of obesity management will increasingly involve treating obesity as a chronic and heterogeneous cardiometabolic disease rather than focusing exclusively on short-term weight reduction.
As oral therapies, multimodal medicines, AI-enabled care models and personalized treatment strategies continue to evolve, success will depend on understanding both scientific advances and the real-world challenges that determine whether innovation can deliver sustained benefits for patients.
Understand how leading U.S. obesity experts view GLP-1 therapies, treatment innovation, personalized care, AI, access barriers and the future of obesity management.
Explore KOL IntelligenceOur data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
Join industry leaders leveraging AI-powered intelligence to make confident, data-driven decisions that accelerate breakthrough treatments and technologies to market.